1. Rice AM, Rivkees SA. Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr1999;134:349-351.
2.
2. Hicks JM, Levy ML, Alexander J, Flaitz CM. Subcutaneous fat necrosis of the newborn and hypercalcemia: case report and review of literature. Pediatr Dermatol. 1993;10:271-276.
3.
3. Finne P, Sanderud J, Aksnes L, et al. Hypercalcemia with increased and unregulated 1,25 dihydroxy vitamin D production in a neonate with fat necrosis. J Pediatr1988;112:792-794.
4.
4. Cook JS, Stone MS, Hansen JR. Hypercalcemia in association with subcutaneous fat necrosis of the newborn: studies of calcium regulating hormones. Pediatrics. 1992;90:93-96.
5.
5. Lee J, Katayama S. Prostaglandins, thromboxanes, and leukotrienes. In: Wilson J, Foster D, eds. Williams Textbook of Endocrinology. Philadelphia: WB Saunders; 1998.
6.
6. Veldhius JD, Kulin HE, Demers LM, Lambert PW. Infantile hypercalcemia with subcutaneous fat necrosis: endocrine studies. J Pediatr1979;95:460-462.
7.
7. Yashuda T, Sunami S, Ogura N, Nakajima H. Infantile hypercalcemia with subcutaneous fat necrosis: report of a case with studies on pathogenesis of hypercalcemia. Acta Paed Scand. 1986;75:1042-1045.
8.
8. Srivastava T, Alon US. Bisphosphonates: From grandparents to grandchildren. Clin Pediatr. 1999;38:687-702.
9.
9. Glorieux F, Bishop N, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339: 947-952.
10.
10. Shoemaker LR. Expanding role of bisphosphonate therapy in children.J Pediatr1999;134:264-267.
